• US FDA grants Orphan Drug Designation to Galidesivir for Marburg virus disease
• Designation provides seven years of market exclusivity in the US upon approval
• Reinforces Galidesivir's potential as a medical and biodefence countermeasure
• Strengthens regulatory and commercial positioning ahead of dose optimization

Island Pharmaceuticals Ltd announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Galidesivir for the post-exposure prophylaxis of Marburg virus disease. This designation provides benefits such as seven years of market exclusivity in the US upon approval, exemption from certain FDA fees, and regulatory support. It highlights Galidesivir's potential as a medical and biodefence countermeasure against high-consequence viral threats. The designation follows significant progress in manufacturing, regulatory, and study activities supporting the FDA Animal Rule pathway.